Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia | NASH, T2DM, Hyperlipoidemia | Preclinical |
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
FG1-H82Q3 | Human | Biotinylated Human FGF-21 Protein, His,Avitag™ |
|
||
FG1-H5243 | Human | Human FGF-21 Protein, His Tag |
|
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
HEC-88473 | HEC-88473; HEC88473 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity | Details |
YH-25724 | YH-25724; YH25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
AP-026 | AP-026; TQA-2226; TQA2226; AP026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
HEC-88473 | HEC-88473; HEC88473 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity | Details |
YH-25724 | YH-25724; YH25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
AP-026 | AP-026; TQA-2226; TQA2226; AP026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
This web search service is supported by Google Inc.